Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Accumulated Expenses (2016 - 2025)

PAVmed has reported Accumulated Expenses over the past 6 years, most recently at $2.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 51.97% year-over-year to $2.5 million; the TTM value through Dec 2025 reached $2.5 million, down 51.97%, while the annual FY2025 figure was $2.5 million, 51.97% down from the prior year.
  • Accumulated Expenses for Q4 2025 was $2.5 million at PAVmed, down from $2.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $6.8 million in Q2 2024 and troughed at $1.1 million in Q1 2021.
  • A 5-year average of $3.6 million and a median of $3.2 million in 2022 define the central range for Accumulated Expenses.
  • Biggest five-year swings in Accumulated Expenses: skyrocketed 208.74% in 2022 and later plummeted 65.69% in 2025.
  • Year by year, Accumulated Expenses stood at $4.3 million in 2021, then fell by 13.01% to $3.7 million in 2022, then soared by 78.84% to $6.6 million in 2023, then fell by 21.88% to $5.2 million in 2024, then plummeted by 51.97% to $2.5 million in 2025.
  • Business Quant data shows Accumulated Expenses for PAVM at $2.5 million in Q4 2025, $2.7 million in Q3 2025, and $2.8 million in Q2 2025.